Skip to main content
SpringerLink
Log in

Adjuvant Therapy of Breast Cancer V

  • Conference proceedings
  • © 1996

Overview

Editors:
  1. Hans Jörg Senn

    1. Department of Medicine C, Kantonsspital, St. Gallen, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Richard D. Gelber

    1. Division of Biostatistics, Dana Farber Cancer Institute, Boston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Aron Goldhirsch

    1. Ospedale Civico, Lugano, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  4. Beat Thürlimann

    1. Department of Medicine C, Kantonsspital, St. Gallen, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 140)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (37 papers)

  1. Front Matter

    Pages I-XIV
    Download chapter PDF

  2. Introduction

    1. The Control of Breast Cancer: A Look into the Future

      • U. Veronesi
      Pages 1-4

  3. Epidemiology and Genetics of Breast Cancer

    1. Familial Breast Cancer

      • B. L. Weber
      Pages 5-16

    2. The Food-Derived Heterocyclic Amines and Breast Cancer: A 1995 Perspective

      • E. G. Synderwine
      Pages 17-25

    3. Menstrual Cycle Timing of Breast Cancer Resection

      • W. J. M. Hrushesky
      Pages 27-40

    4. Summary

      • M. H. N. Tattersall
      Pages 41-42

  5. Prognosis of Response and Tumor Markers

    1. Review of Known Prognostic Variables

      • M. Kaufmann
      Pages 77-87

    2. Prognostic Variables and Future Predictors of Behaviour and Response

      • B. A. Gusterson
      Pages 89-100

    3. Serum (Circulating) Tumor Markers for Breast Cancer

      • D. F. Hayes
      Pages 101-113

    4. Summary

      • M. Baum
      Pages 115-122

  6. Screening for Breast Cancer and Treatment of Early Lesions (Ductal Carcinoma In Situ)

    1. A Critical Review of Screening for Breast Cancer

      • M. Rosselli Del Turco
      Pages 123-130

    2. Ductal Carcinoma In Situ

      • R. G. Margolese
      Pages 131-138

    3. Intraductal Breast Carcinoma: Experiences from The Breast Center in Van Nuys, California

      • M. J. Silverstein, D. N. Poller, A. Barth, J. R. Waisman, J. A. Jensen, R. Masetti et al.
      Pages 139-153

    4. Summary

      • John F. Forbes
      Pages 155-157

  7. Surgery for Breast Cancer: Special Issues

    1. Surgical Treatment of Breast Cancer Relapse

      • R. G. Margolese
      Pages 159-167

    2. Primary and Secondary Breast Reconstruction with Special Emphasis on the Use of Prostheses

      • J. Y. Petit, M. Rietjens, C. Garusi, D. Capko
      Pages 169-175
Back to top

Keywords

About this book

We often hear physicians, health care professionals, poli­ ticians, and patient advocates that "nothing has happened in the treatment of breast cancer," since patients with breast cancer, the most frequent neoplastic condition in women in industrialized countries, are continuing to suffer relapse and succumb to this dreadful disease! This negativistic attitude does not seem to be justified, but, why is the transmission of clinical trial results into general practice, and with it progress, such a slow process? After many decades of frustrating stagnation of long-term survival expectations, in all stages of early, oper/lble breast cancer treated only by surgery and locoregional radio­ therapy, adjuvant systemic therapy (chemo- as well as endocrine treatments) clearly showed to significantly benefit in terms of disease-free and overall survival. This evolution has been extensively expounded on by the Worldwide Oxford Overview and the Expert Consensus Panel at the fourth International Conference 'on Adjuvant Therapy of Primary Breast Cancer in St. Gallen (Early Breast Cancer Trialists' Collaborative Group 1992; Glick et al. 1992). What has happened since then? During the past 3-5 years, several new concepts and treatment strategies have emerged and have been studied in various major breast cancer groups and treatment centers worldwide. Some of these can already be considered to assist in the primary treatment of operable breast cancer today, while others are . still undergoing clini,cal trials for better definition of their practical usefulness.

Editors and Affiliations

  • Department of Medicine C, Kantonsspital, St. Gallen, Switzerland

    Hans Jörg Senn, Beat Thürlimann

  • Division of Biostatistics, Dana Farber Cancer Institute, Boston, USA

    Richard D. Gelber

  • Ospedale Civico, Lugano, Switzerland

    Aron Goldhirsch

Bibliographic Information

  • Book Title: Adjuvant Therapy of Breast Cancer V

  • Editors: Hans Jörg Senn, Richard D. Gelber, Aron Goldhirsch, Beat Thürlimann

  • Series Title: Recent Results in Cancer Research

  • DOI: https://doi.org/10.1007/978-3-642-79278-6

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1996

  • Softcover ISBN: 978-3-642-79280-9Published: 25 December 2011

  • eBook ISBN: 978-3-642-79278-6Published: 06 December 2012

  • Series ISSN: 0080-0015

  • Series E-ISSN: 2197-6767

  • Edition Number: 1

  • Number of Pages: XIV, 342

  • Topics: Oncology, Gynecology

Publish with us

Policies and ethics

Back to top

Search

Navigation